Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on July 17.

Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE, Sinovant is developing a pipeline of 10 clinical stage candidates, plus one preclinical candidate, for Greater China and other Asian markets. Its pipeline spans several therapeutic areas, including cancer, gastroenterology and infectious disease. Roivant helped Sinovant build its pipeline, and Sinovant began operations last year...